Mandate

Vinge advises Karl Hedin and the minority owners in connection with the sale of AB Karl Hedin Emballage to DTE

Vinge has advised Karl Hedin and the minority owners in connection with the sale of AB Karl Hedin Emballage to Dansk Træemballage A/S (”DTE”).

DTE is the largest manufacturer of wooden packaging in the Nordic region, with approximately 625 employees and a turnover of SEK 1.9 billion. DTE has eight production sites in Denmark, nine production sites in Norway, two production sites in Sweden and a trading company in Germany. AB Karl Hedin Emballage has ten production sites in Sweden and one in Estonia and employs around 275 people. Together, the two companies will have a turnover of around SEK 2.5 billion and around 900 employees. AB Karl Hedin Emballage will continue to operate under the same name and brand.

Vinge’s team primarily consisted of Jonas Johansson, Johan Winnerblad, Egil Svensson and Olof Löfvenberg (M&A), David Olander and Dagne Sabockis (EU and Competition), Eva Fredrikson and Siri Blomberg (Commercial Agreements), Niclas Winnberg and Simon Gille-Johnson (Real Estate), Alva Skott (Intellectual Property) and Jessica Öijer (Transaction Support Coordinator).

Read the client’s press release.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025